~~U.S.~~UNITED ~~SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549~~STATES

~~Form~~SECURITIES ~~10-K~~AND EXCHANGE COMMISSION

~~Mark~~Washington, ~~One~~D.C. 20549

☒FORM ~~ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~10-K

~~For~~(Mark ~~the fiscal year ended September 30, 2024~~One)

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the fiscal year ended September 30, 2025

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from _____________ to _____________

Commission file number 333-199193

~~For~~Medicale ~~the~~Corp. ~~transition~~(Exact ~~period~~name ~~from~~of ~~______~~registrant toas ~~_______~~specified in its charter)

Commission File No. 333-250025

Nevada

98-1556944

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

MEDICALE CORP. (Exact name of registrant as specified in its charter)

9314 Forest Hill Blvd #929 Wellington, FL		33411
(Address of principal executive offices)		(Zip Code)

~~Nevada~~Registrant’s ~~(State~~telephone ornumber, ~~Other~~including area ~~Jurisdiction~~code: ~~of Incorporation or Organization) 8000 (Primary Standard Industrial Classification Number) EIN 98~~407-~~1556944 (IRS Employer Identification Number)~~245-7339

9314 Forest Hill Blvd #929

Wellington, FL 33411

(407) 245-7339

[email protected]

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive offices)

Incorp Services, Inc

3773 Howard Hughes Parkway Suite 500 S

Las Vegas, NV 89169-6014

+1 (702) 866-2500

(Name, address, including zip code, and telephone number,

including area code, of agent for service)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered ~~N/A~~None ~~N/A~~None None

Securities registered pursuant to ~~section~~Section 12(g) of the Act: ~~None~~

~~Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒.~~N/A

~~Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15~~(d)Title of ~~the Act. Yes ☐ No ☒~~class)

Indicate by ~~checkmark~~check ~~whether~~mark ~~the~~if ~~issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of~~ the ~~Exchange~~registrant ~~Act~~is ~~during the past 12 months (or for such shorter period~~a ~~that~~well-known ~~the~~seasoned ~~registrant was required to file such reports)~~issuer, ~~and~~as ~~(2)~~defined ~~has~~in ~~been~~Rule ~~subject~~405 ~~to such filing requirements for~~ the ~~past~~Securities ~~90 days~~Act. Yes ☒ No ☐ No ☒

Indicate by check mark ~~whether~~if the registrant ~~has~~ ~~submitted~~is ~~electronically and posted on its corporate Web site, if any, every Interactive Data File~~ not required to befile ~~submitted~~reports ~~and posted~~ pursuant to ~~Rule~~Section ~~405~~13 ofor ~~Regulation~~Section ~~S-T~~ 15(§d) ~~232.405~~ of ~~this chapter) during~~ the ~~preceding~~Act ~~12 months (or for such shorter period that the registrant was required to submit and post such files).~~ Yes ~~☒ No~~ ☐ No ☒

Indicate by check mark whether the registrant is(1) ahas ~~large~~filed ~~accelerated~~all ~~filer,~~reports anrequired ~~accelerated~~to ~~filer,~~be afiled ~~non-accelerated~~by ~~filer,~~Section a13 ~~smaller~~or ~~reporting~~15(d) ~~company,~~of orthe anSecurities ~~emerging~~Exchange ~~growth~~Act ~~company. See~~of 1934 during the ~~definitions~~preceding of12 ~~“large~~months (or ~~accelerated~~for ~~filer,”~~such ~~“accelerated~~shorter ~~filer,”~~period ~~“smaller~~that ~~reporting~~the ~~company~~registrant was required to file such reports),” and ~~“emerging~~ ~~growth~~(2) ~~company”~~has inbeen ~~Rule~~subject ~~12b-2~~to ofsuch filing requirements for the ~~Exchange~~last ~~Act~~90 days. Yes ☒ No ☐

~~Large~~Indicate ~~accelerated~~by ~~filer~~check ☐mark ~~Accelerated~~whether ~~filer~~the ☐registrant has ~~Non~~submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-~~accelerated~~T ~~filer~~(§232.405 of ☒this ~~Smaller~~chapter) ~~reporting~~during ~~company~~the ☒preceding ~~Emerging~~12 ~~growth~~months ~~company~~(or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant'’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by ~~checkmark~~check mark whether the registrant is is a ~~shell~~large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, ~~(as~~or ~~defined~~an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act). ~~Yes ☐ No ☒~~

AsLarge ofaccelerated ~~March~~filer ~~31,~~☐ ~~2024~~Accelerated ~~the~~filer ~~last~~☐ ~~business~~Non-accelerated ~~day of~~Filer ~~the~~☒ ~~registrant’s~~Smaller ~~most~~reporting ~~recently~~company ~~completed~~☒ ~~second~~Emerging ~~fiscal~~Growth ~~quarter,~~Company ~~the aggregate market value of the voting and non-voting common equity held by non-affiliates was $0.~~☒

Class	Outstanding as of January 13, 2025
Common Stock: $0.0001	5,920,000

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of Common Stock held by non-affiliates of the Registrant on March 31, 2025, was $489,600 based on a $0.18 average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.

5,920,000 shares of common stock as of January 9, 2026.

TABLE OF CONTENTS

PART 1
PART I
ITEM 1	Description of Business	1
ITEM 1.	BUSINESS		4
ITEM 1A	Risk Factors	1
ITEM 1A.	RISK FACTORS		4
ITEM 1B	Unresolved Staff Comments	1
ITEM 1B.	UNRESOLVED STAFF COMMENTS		4
ITEM 1C	Cybersecurity	1
ITEM 1C.	CYBERSECURITY		5
ITEM 2	Properties	1
ITEM 2.	PROPERTIES		5
ITEM 3	Legal Proceedings	1
ITEM 3.	LEGAL PROCEEDINGS		5
ITEM 4	Mine Safety Disclosures	1
ITEM 4.	MINE SAFETY DISCLOSURES		5
PART II
ITEM 5	Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities	2
ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES		6
ITEM 6	[Reserved]	2
ITEM 6.	SELECTED FINANCIAL DATA		6
ITEM 7	Management's Discussion and Analysis of Financial Condition and Results of Operations	2
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		7
ITEM 7A	Quantitative and Qualitative Disclosures about Market Risk	4
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		9
ITEM 8	Financial Statements and Supplementary Data	4
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA		9
ITEM 9	Changes In and Disagreements with Accountants on Accounting and Financial Disclosure	4
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE		10
ITEM 9A	Controls and Procedures	4
ITEM 9A.	CONTROLS AND PROCEDURES		10
ITEM 9B	Other Information	6
ITEM 9B.	OTHER INFORMATION		11
ITEM 9C	Disclosure Regarding foreign Jurisdictions that Prevent Inspections	6
PART III
PART III
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE		12
ITEM 10	Directors, Executive Officers, Promoters and Control Persons of the Company	7
ITEM 11.	EXECUTIVE COMPENSATION		14
ITEM 11	Executive Compensation	8
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS		15
ITEM 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	9
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE		15
ITEM 13	Certain Relationships and Related Transactions	10
ITEM 14.	PRINCIPAL ACCOUNTING FEES AND SERVICES		15
ITEM 14	Principal Accountant Fees and Services	10
PART IV
PART IV
ITEM 15.	EXHIBITS, FINANCIAL STATEMENT SCHEDULES		16
ITEM 15	Exhibits	12
ITEM 16.	FORM 10-K SUMMARY		16
ITEM 16	Form 10-K Summary	12
SIGNATURES			17

FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements. These statements relate to future events or our future financial performance. ~~These~~In ~~statements~~some ~~often~~cases, you can beidentify ~~identified~~forward-looking statements by ~~the~~terminology ~~use of terms~~ such as "“may”," ~~"will~~“should”," ~~"expect~~“expects”," ~~"believe~~“plans”," ~~"anticipate~~“anticipates”," “believes”, ~~"estimate~~“estimates”," ~~"approximate"~~ “predicts”, “potential” or "“continue,"” or the negative of ~~thereof.~~these Weterms ~~intend~~or ~~that~~other ~~such~~comparable ~~forward-looking~~terminology. ~~statements~~These ~~be subject to the safe harbors for such~~ statements. Weare ~~wish~~only topredictions ~~caution~~and ~~readers~~involve ~~not~~known toand ~~place~~unknown ~~undue~~risks, ~~reliance~~uncertainties and onother ~~any such forward-looking statements~~factors, ~~which~~including ~~speak only as of~~ the ~~date~~ ~~made.~~risks ~~Any forward-looking statements represent management's best judgment as to what may occur~~ in the ~~future.~~section ~~However,~~entitled ~~forward-looking statements~~“Risk ~~are~~Factors” ~~subject to risks, uncertainties and important factors beyond our control~~ that ~~could~~may cause ~~actual~~our ~~results~~or ~~and~~our ~~events~~industry’s toactual ~~differ materially from historical~~ results, levels of ~~operations~~activity, ~~and~~performance ~~events and those presently anticipated~~ or ~~projected.~~achievements Weto ~~disclaim~~be ~~any~~materially ~~obligation subsequently~~different tofrom ~~revise~~ any ~~forward-looking~~future ~~statements~~results, tolevels ~~reflect~~of ~~events~~activity, performance or ~~circumstances~~achievements ~~after~~expressed ~~the date of such statement~~ or toimplied ~~reflect the~~by ~~occurrence~~these offorward-looking ~~anticipated or unanticipated events~~statements.

iiAlthough we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this annual report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this annual report and unless otherwise indicated, the terms “we”, “us”, “our” and “the Company” mean Medicale Corp., unless otherwise indicated.

PART I

~~Item~~ITEM 1. ~~Description of Business~~BUSINESS

~~GENERAL~~Our ~~INFORMATION ABOUT OUR COMPANY~~Company

Medicale Corp (“we,” “our” or the “Company”) was incorporated in the State of Nevada on August 17, 2020. To date we have not generated revenue from our business operations. Furthermore, as we are still in the early stages of developing our business and expect to operate at a loss as we grow our business. There is little historical financial information about our Company upon which to base an evaluation of our performance or to make a decision regarding an investment in our shares. We cannot guarantee that we will be successful in our business operations or that we will achieve significant, if any, level of market acceptance for our proposed business operations and products. Our business could be subject to any or all of the problems, expenses, delays and risks inherent in the establishment of a new business enterprise, including limited capital resources, possible changes in consumer interest, possible cost overruns due to price and cost increases in services or products we require.

We have never been subject to any bankruptcy proceedings. The principal place of business is now located at 9314 Forest Hill Blvd #929, Wellington, FL 33411. Our telephone number is (407)245-7339.

As of the date of this report, the Company ~~had~~ had not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and continuing the Company’s public reporting.

~~Item~~Our ~~1A.~~Current ~~Risk Factors.~~Business

~~Not~~As ~~required~~of ~~for~~the ~~Smaller~~date ~~reporting~~of ~~companies~~this report, the Company had not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and continuing the Company’s public reporting.

~~Item 1B. Unresolved Staff Comments.~~Employees

~~Not~~We ~~required~~have ~~for~~no ~~Smaller~~employees ~~reporting~~and ~~companies~~our officers and directors furnish their time to the development of our Company at no cost.

~~Item~~ITEM 1C1A. ~~Cybersecurity~~RISK FACTORS

~~Risk~~As ~~Management~~a ~~and~~“smaller ~~Strategy~~reporting company”, we are not required to provide the information required by this Item.

~~Currently,~~ITEM ~~the only cybersecurity risk is from the use of websites associated with the Company~~1B. ~~All~~UNRESOLVED ~~hosting~~STAFF ~~and hosting related services of these websites are engaged via reputable companies such as Namecheap, Godaddy and Cloudflare.~~COMMENTS

~~These~~As aforementioned companies utilize the latest industrial standards for security and data protection. Safeguards include continuous server monitoring, server and infrastructure security configuration consistently applied across all servers, firewall protection, anti-malware protection, a ~~dedicated~~“smaller ~~internal~~reporting ~~security team~~company”, ~~applied~~we ~~Open~~are ~~Worldwide~~not ~~Application~~required ~~Security~~to ~~Project~~provide ~~secure~~the ~~coding~~information ~~practices,~~required ~~and~~by ~~regular~~this ~~data backups~~Item.

~~Item 2. Properties.~~4

~~Currently~~ITEM ~~we don’t own any properties~~1C. ~~Our business office is located at 9314 Forest Hill Blvd #929, Wellington, FL 33411.~~CYBERSECURITY

~~Item~~We 3have implemented cybersecurity risk management procedures, in accordance with our risk profile and business size. ~~Legal~~We ~~Proceedings~~rely on our information technology to operate our business. As such, we have policies and processes designed to protect our information technology systems, some of which are managed by third parties, and resolve issues in a timely manner in the event of a cybersecurity threat or incident.

We ~~are~~have ~~not~~designed ~~currently~~our abusiness ~~party~~applications to minimize ~~any~~the ~~legal~~impact ~~proceedings~~that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. We seek to further mitigate cybersecurity risks through a combination of monitoring and detection activities, use of anti-malware applications, employee training, quality audits and wecommunication ~~are~~and ~~not~~reporting ~~aware~~structures, among other processes. We have a trained group of people to carry out the activities of monitoring and detection of cybersecurity threats and respond to any ~~pending~~cybersecurity threats or incidents. The Head of IT department is responsible for oversight of cybersecurity risks and addressing potential ~~legal~~cybersecurity ~~actions~~risks to business programs, employees, clients, vendors and partners. The Head of IT Department reports to our Chief Executive Officer who reports to the Audit Committee at the board-level, as appropriate.

~~Item~~As 4.of ~~Mine~~September ~~Safety~~30, ~~Disclosures~~2025, we have not identified an indication of a cybersecurity incident that would have a material impact on our business and consolidated financial statements.

~~Not~~ITEM ~~Applicable~~2. PROPERTIES

1Our principal executive office is located at 9314 Forest Hill Blvd #929, Wellington, FL 33411. We believe that our facilities are generally adequate for our current needs, and that suitable additional office space will be available as needed in the foreseeable future.

~~PART~~ITEM II3. LEGAL PROCEEDINGS

~~Item~~We 5.are ~~Market~~not ~~for~~currently ~~Registrant’s~~a ~~Common~~party ~~Equity,~~to ~~Related~~any legal ~~Stockholder Matters~~proceedings, and ~~Issuer~~we ~~Purchases~~are not aware of ~~Equity~~any ~~Securities~~pending or potential legal actions.

~~The~~ITEM ~~company~~4. ~~stock~~MINE isSAFETY ~~not trading at the moment.~~DISCLOSURES

~~Registered~~Not ~~Holders of our Common Stock~~Applicable.

~~As of September 30, 2024, there were approximately 32 record owners of our common stock including director.~~5

~~Dividends~~PART II

~~Recent~~Market ~~Sales of Unregistered Securities~~Information

~~During~~There is a limited public market for our ~~fiscal~~common shares. ~~years~~Our ~~ended~~common ~~September~~shares ~~30,~~are listed for quotation on the Pink sheets of the OTC Markets under the trading symbol “MCLE”. ~~2024~~Trading in stocks quoted on the Pink Sheets is often thin and ~~2023,~~is wecharacterized ~~had~~by nowide ~~sales~~fluctuations ofin ~~unregistered~~trading ~~shares~~prices due to many factors that may be unrelated to a company’s operations or business prospects.

~~Issuer~~Pink ~~Purchases~~Sheet securities are not listed or traded on the floor of ~~Equity~~an ~~Securities~~organized national or regional stock exchange. Instead, OTC Pink Sheet securities transactions are conducted through a telephone and computer network connecting dealers in stocks. Pink Sheet issuers are traditionally smaller companies that do not meet the financial and other listing requirements of a regional or national stock exchange.

~~During the fiscal year ended September 30, 2024, and 2023 the Company did not repurchase any shares of its Common Stock.~~Holders

~~Item~~As 6.of ~~[Reserved]~~January 9, 2026, we had 11 shareholders of record of our common stock with 5,920,000 shares of common stock outstanding.

~~Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations~~Dividends

We ~~are~~have anot ~~development~~paid ~~stage~~any ~~corporation~~cash ~~with~~dividends ~~limited~~to our shareholders. ~~operations~~The ~~and~~declaration noof ~~revenues~~any ~~from~~future ~~our~~cash ~~business~~dividends ~~operations.~~is ~~Our~~at ~~auditors~~the ~~have~~discretion ~~issued~~of aour ~~going~~board ~~concern~~of ~~opinion.~~directors ~~This~~and ~~means~~depends ~~that~~upon our ~~auditors believe~~earnings, ~~there~~if isany, ~~substantial~~our capital ~~doubt~~requirements ~~that~~and wefinancial ~~can~~position, ~~continue~~our asgeneral aneconomic ~~on-going~~conditions, ~~business~~and ~~for~~other ~~the~~pertinent ~~next twelve months~~conditions. WeIt dois ~~not~~our ~~anticipate~~present ~~that~~intention wenot ~~will~~to ~~generate~~pay ~~significant~~any ~~revenues~~cash ~~until~~dividends wein ~~have~~the ~~raised~~foreseeable ~~the~~future, ~~funds~~but ~~necessary~~rather to ~~conduct~~reinvest aearnings, ~~marketing~~if ~~program~~any, in our business operations.

~~PLAN~~Equity OFCompensation ~~OPERATION~~Plan Information

~~FISCAL~~We ~~YEAR~~do ~~ENDED~~not ~~SEPTEMBER~~have ~~30,~~any ~~2024 COMPARED~~equity TOcompensation ~~FISCAL YEAR ENDED SEPTEMBER 30, 2024~~plans.

~~Our~~Recent ~~net~~Sales ~~loss~~of ~~for~~Unregistered ~~the~~Securities; ~~fiscal year ended~~Use ~~September 30, 2024 was $58,213 compared to a net loss~~ of ~~$37,138~~Proceeds ~~during~~from ~~the~~Registered ~~fiscal year ended September 30, 2023. In September 30, 2024 and September 30, 2023 the Company had not generated any revenue respectively.~~Securities

~~All revenue generated by the Company was done so by operations that have been discontinued.~~None

~~Expenses~~Purchase ~~incurred~~of ~~were~~Equity ~~$54,707~~Securities ~~during~~by ~~fiscal year ended September 30, 2024 compared to $37,593 during fiscal year ended September 30, 2023. Expenses increased due to~~ the Issuer ~~Company’s~~and ~~operational~~Affiliated ~~activities.~~Purchasers

~~The~~We ~~number~~did not purchase any of our shares ~~outstanding~~ ~~was~~of ~~5,920,000~~common ~~for~~stock ~~the~~or ~~fiscal~~other ~~year~~securities ~~ended~~during ~~September~~our ~~30,~~fourth ~~2024~~quarter ~~and~~of our fiscal year ended September 30, ~~2024~~2025.

2ITEM 6. SELECTED FINANCIAL DATA

~~LIQUIDITY~~As ~~AND~~a ~~CAPITAL~~“smaller ~~RESOURCES~~reporting company”, we are not required to provide the information required by this Item.

~~FISCAL YEAR ENDED September 30, 2024 and 2023.~~6

AsITEM of7. ~~September~~MANAGEMENT’S ~~30,~~DISCUSSION ~~2024,~~AND ~~our~~ANALYSIS ~~total~~OF ~~assets~~FINANCIAL ~~were $159.~~CONDITION AND RESULTS OF OPERATIONS

AsThe offollowing ~~September~~discussion 30should be read in conjunction with our financial statements, ~~2023~~including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our ~~total~~plans, ~~assets~~estimates ~~were~~and beliefs. Our actual results could differ materially from those discussed ~~$159~~in the forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this Annual Report. Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

~~Cash~~Results ~~Flows~~of ~~from Operating Activities~~Operations

WeThe ~~have~~following ~~not~~summary ~~generated~~of ~~positive~~our ~~cash~~results ~~flows~~of operations ~~from~~should ~~operating~~be ~~activities.~~read ~~For~~in ~~the~~conjunction ~~fiscal~~with ~~year~~our ~~ended~~financial ~~September~~statements ~~30,~~for ~~2024, net cash flows used in operating activities was $83,585. For~~ the ~~fiscal~~ year ended September 30, ~~2023,~~2025 ~~net~~and ~~cash~~2024 ~~flows~~which ~~used~~are inincluded ~~operating activities was $25,739~~herein.

~~Cash~~Year ~~Flows~~ended ~~from~~September ~~Investing~~30, ~~Activities~~2025 compared to year ended September 30, 2024

We have not generated cash flows from investing activities for the fiscal years ended September 30, 2024, and 2023.

	Year Ended
	September 30,
	2025		2024		Changes			%

Operating expenses	$	33,493	$	54,707	$	(21,214	)		(39%	)
Other expenses		7,660		3,506		4,154			118%
Net Loss	$	41,153	$	58,213	$	(17,060	)		(29%	)

~~Cash~~Our ~~Flows~~net ~~from~~loss ~~Financing~~for ~~Activities~~the year ended September 30, 2025 was $41,153 compared with net loss of $58,213 for the year ended September 30, 2024 due to the decrease in consulting fees.

WeLiquidity ~~have~~and financed our operations primarily from either advances from our third party investors or the issuance of equity. For the fiscal year ended September 30, 2024, net cash provided by financing activities was $83,585. For the fiscal year ended September 30, 2023, net cash provided by financing activities was $25,898.Capital

~~OFF-BALANCE~~Working ~~SHEET ARRANGEMENTS~~Capital

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

	As of			As of
	September 30,			September 30,
	2025			2024			Changes			%

Current Assets	$	–		$	159		$	(159	)		(100%	)
Current Liabilities		33,652			15,507			18,145			117%
Working Capital Deficiency	$	(33,652	)	$	(15,348	)	$	17,986			(117%	)

~~GOING~~As ~~CONCERN~~at September 30, 2025 and September 30, 2024, our Company had cash of $0 and $159, respectively.

~~There~~As isat noSeptember ~~historical~~30, ~~financial~~2025, ~~information~~our ~~about us~~Company ~~upon~~had ~~which~~current liabilities ~~to base an evaluation~~ of ~~our~~$33,652 ~~performance.~~as Wecompared ~~are~~to in$15,507 ~~start-up~~as ~~stage~~of ~~operations~~September ~~and~~30, ~~have not generated any revenues~~2024. WeThe ~~cannot guarantee~~increase ~~we will be successful~~ in ~~our~~current ~~business~~liabilities ~~operations.~~was ~~Our~~due ~~business is subject~~ to ~~risks inherent in~~ the ~~establishment~~increase ~~of a new business~~in ~~enterprise~~accounts payable, ~~including~~accrued ~~limited~~liabilities ~~capital resources~~ and ~~possible~~accrued ~~cost~~interest ~~overruns due to price and cost increases in services and products~~payable.

WeAs ~~have~~at noSeptember ~~assurance~~30, ~~that~~2025, ~~future~~our ~~financing~~Company ~~will be~~had ~~available~~a toworking capital usdeficiency onof ~~acceptable~~$33,652 ~~terms.~~compared Ifwith ~~financing~~a isworking ~~not~~capital ~~available~~deficit onof ~~satisfactory terms~~$15,348 weas ~~may~~at beSeptember ~~unable~~30, to2024. ~~continue,~~The ~~develop~~increase orin working capital ~~expand~~deficit ~~our~~was ~~operations.~~primarily ~~Equity~~due ~~financing~~to ~~could~~the ~~result~~increase in ~~additional~~accounts ~~dilution~~payable, toaccrued ~~existing~~liabilities ~~shareholders~~and accrued interest payable.

The extent of the impact of the coronavirus (“COVID-19”) outbreak on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions and the impact of COVID-19 on the overall economy, all of which are highly uncertain and cannot be predicted. If the overall economy is impacted for an extended period, the Company’s future operating results may be materially adversely affected.7

3Cash Flows

Critical Accounting Policies

	Year Ended
	September 30,
	2025			2024			Changes			%

Cash flows used in operating activities	$	(23,008	)	$	(83,585	)	$	60,577			(72%	)
Cash flows provided by financing activities		22,849			83,585			(60,736	)		(73%	)
Net changes in cash	$	(159	)	$	–		$	(159	)		–

~~The~~Cash ~~discussion~~Flow ~~and~~from ~~analysis~~Operating of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.Activities

~~Use~~We ofhave ~~Estimates~~not generated positive cash flow from operating activities. During the year ended September 30, 2025, net cash used in operating activities was $23,008 compared to $83,585 used during the year ended September 30, 2024.

~~The~~Cash ~~preparation~~flows ofused ~~financial~~in ~~statements~~operating inactivities ~~conformity~~during ~~with~~the ~~accounting~~year ~~principles~~ended ~~generally~~September ~~accepted~~30, in2025, ~~the~~comprised ~~United States~~ of ~~America~~a ~~requires~~net ~~management~~loss ~~to make estimates and assumptions that affect the reported amounts~~ of ~~assets~~$41,153 ~~and~~reduced ~~liabilities~~by ~~and~~a ~~disclosure~~net ofchange ~~contingent~~in ~~assets~~operating ~~and~~ liabilities ~~at the date~~ of ~~the financial statements~~$18,145. ~~The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.~~

~~Item~~Cash ~~7A.~~flows ~~Quantitative~~used ~~and~~in ~~Qualitative~~operating ~~Disclosures~~activities ~~about~~during the ~~Market~~year ~~Risk~~ended September 30, 2024, comprised of a net loss of $58,213, increased by a net change in operating liabilities of $25,372.

~~Not~~Cash ~~applicable~~Flow tofrom ~~smaller~~Investing ~~reporting companies.~~Activities

~~Item~~During 8.the ~~Financial~~year ~~Statements~~ended September 30, 2025 and ~~Supplementary~~2024, our ~~Data~~Company did not have any investing activities.

~~The~~Cash ~~Company’s~~Flow ~~Financial~~from ~~Statements~~Financing required by Item 8, together with the reports thereon of the Independent Registered Public Accounting Firm are set forth on pages F-1 through F-9 of this report and are incorporated by reference in this Item 8.Activities

~~Item~~During 9.the ~~Changes~~year inended September 30, 2025 and ~~Disagreements~~2024, net ~~with~~cash ~~Accounting~~provided by financing activities was $22,849 and ~~Financial~~$83,585 ~~Disclosures~~for proceed from the issuance of convertible notes to non-affiliates for paying operating expenses, respectively.

~~None.~~Going Concern

~~Item~~As 9Aof September 30, 2025, we had an accumulated deficit of $216,998. ~~Controls~~We ~~and~~believe ~~Procedures~~that its existing capital resources may not be adequate to enable it to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. The accompanying condensed financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. If we fail to generate positive cash flow or obtain additional financing, when required, we may have to modify, delay, or abandon some or all of our future business plans.

~~Disclosure~~Off-Balance ~~Controls~~Sheet ~~and Procedures~~Arrangements

~~Disclosure~~We ~~controls~~have ~~and~~no ~~procedures~~off-balance ~~are~~sheet ~~designed~~arrangements that tohave ~~ensure~~or ~~that~~are ~~information~~reasonably ~~required~~likely to behave ~~disclosed~~a incurrent ~~the reports filed~~ or ~~submitted~~future ~~under~~effect ~~the~~on ~~Exchange~~our ~~Act~~financial ~~is recorded~~condition, ~~processed,~~changes ~~summarized and reported, within the time period specified~~ in ~~the~~financial ~~SEC’s rules and forms~~condition, ~~and that such information is accumulated and communicated~~revenues toor ~~management~~expenses, ~~including~~results ~~the CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures. Our management necessarily applied its judgment in assessing the costs and benefits~~ of ~~such controls and procedures~~operations, ~~which~~liquidity, bycapital ~~their~~expenditures ~~nature,~~or ~~can~~capital ~~provide~~resources ~~only~~that ~~reasonable assurance~~are ~~regarding~~material ~~management’s~~to ~~control objectives~~stockholders.

~~Our~~Critical ~~management,~~Accounting with the participation of our CEO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Report. Based upon this evaluation, our CEO concluded that our disclosure controls and procedures were not effective because of the identification of a material weakness in our internal control over financial reporting which is described below.Policies

4The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements’ estimates or assumptions could have a material impact on our financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Our financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented.

~~Management’s~~Recent ~~Report~~Accounting ~~on Internal Control Over Financial Reporting~~Pronouncements

~~Our~~Management ~~management~~has isconsidered ~~responsible~~all ~~for~~recent ~~establishing~~accounting ~~and~~pronouncements ~~maintaining adequate internal control over financial reporting, as such term is defined in Exchange Rule 13a-15(f)~~issued. Our ~~internal~~company’s ~~control over~~management ~~financial~~believes ~~reporting~~that isthese arecent ~~process~~pronouncements ~~designed~~will tonot ~~provide~~have ~~reasonable~~a ~~assurance~~material toeffect ~~our~~on ~~management and board of directors regarding the~~our ~~reliability of~~ financial ~~reporting and the preparation of the financial~~ statements ~~for external purposes in accordance with U~~.~~S. GAAP.~~

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP and our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements.8

~~Because~~ITEM ~~of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements~~7A. ~~All~~QUANTITATIVE ~~internal~~AND ~~control~~QUALITATIVE ~~systems,~~DISCLOSURES noABOUT ~~matter~~MARKET how well designed, have inherent limitations, including the possibility of human error and the circumvention of overriding controls. Accordingly, even effective internal control over financial reporting can provide only reasonable assurance with respect to financial statement preparation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.RISK

~~Our~~Not ~~management assessed the effectiveness of our internal control over financial reporting as of September 30, 2024~~Applicable. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Tread way Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based on this evaluation, management concluded that that our internal control over financial reporting was not effective as of September 30, 2024. Our CEO concluded we have a material weakness due to lack of segregation of duties, a limited corporate governance structure, and a lack of a formal management review process over preparation of financial information. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

~~Our~~ITEM ~~size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties within our system of internal control~~8. ~~Therefore,~~ ~~while~~FINANCIAL ~~there~~STATEMENTS ~~are~~AND ~~some~~SUPPLEMENTARY ~~compensating controls in place, it is difficult to ensure effective segregation of accounting and financial reporting duties. Management reported the following material weaknesses:~~DATA

·MEDICALE Certain reports that we prepare, and accounting and reporting conclusions reached in connection with the financial statement preparation process are not subjected to a formal review process that includes multiple levels of review and are not submitted timely to the Board of Directors for review or approval; and · Lack of segregation of duties in certain accounting and financial reporting processes including the initiation, processing, recording and approval of disbursements; · Our corporate governance responsibilities are performed by the Board of Directors, none of whom are independent under applicable standards; we do not have an audit committee or compensation committeeCORP. Our Board of Directors acts primarily by written consent without meetings which results in several of our corporate governance functions not being performed concurrent (or timely) with the underlying transactions, including evaluation of the application of accounting principles and disclosures. · The Company lacks adequate financial reporting capabilities – Due to the minimal operations and small size of the Company we have not employed individuals that have the necessary accounting knowledge and expertise to ensure accurate financial reporting under US GAAP. · The Company lacks appropriate information technology controls – As of September 30, 2024, the Company retains copies of all financial data and material agreements; however, there is no formal procedure or evidence of normal backup of the Company’s data or off-site storage of data in the event of theft, misplacement, or loss due to unmitigated factors.

5AUDITED FINANCIAL STATEMENTS

~~While~~SEPTEMBER ~~we strive to segregate duties as much as practicable~~30, ~~there~~2025 isAND an insufficient volume of transactions at this point in time to justify additional full-time staff. We believe that this is typical in many development stage companies. We may not be able to fully remediate the material weakness until we commence operations at which time, we would expect to hire more staff. We will continue to monitor and assess the costs and benefits of additional staffing.2024

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to the SEC rules that permit us to provide only management’s report in this Annual Report.

		Page

Report of Independent Registered Public Accounting Firm		F-1

Balance Sheets		F-2

Statements of Operations		F-3

Statements of Changes in Stockholders’ Deficit		F-4

Statements of Cash Flows		F-5

Notes to the Financial Statements		F-6

~~Changes in Internal Control Over Financial Reporting~~9

~~There~~REPORT ~~were~~OF noINDEPENDENT ~~changes~~REGISTERED inPUBLIC ~~our internal control~~ACCOUNTING over financial reporting that occurred during the Year ended September 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.FIRM

~~Item~~VICTOR ~~9B.~~MOKUOLU, ~~Other~~CPA ~~Information.~~PLLC Accounting | Advisory | Assurance & Audit | Tax

~~During~~To the ~~quarter~~Board ~~ended September 30, 2024, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a)~~ of ~~Regulation~~Directors ~~S-K.~~and Stockholders

~~Item~~Medicale 9CCorp. ~~Disclosures Regarding Foreign Jurisdictions that Prevent Inspections.~~

~~Not~~Opinion ~~Applicable.~~on the Financial Statements

6We have audited the accompanying balance sheets of Medicale Corp. (the Company) as of September 30, 2025 and September 30, 2024, and the related statements of operations, stockholders’ deficit, and cash flows for the two years then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2025, and September 30, 2024, and the results of its operations and its cash flows for the two years ended September 30, 2025, in conformity with accounting principles generally accepted in the United States of America.

~~PART~~Substantial ~~III~~doubt about the Company’s ability to continue as a Going Concern

~~Item~~The 10accompanying financial statements have been prepared assuming the Company will continue as a going concern. ~~Directors,~~As ~~Executive~~discussed ~~Officers~~in Note 2 to the financial statements, the Company has suffered recurring losses and ~~Corporate~~has ~~Governance~~not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~The~~Basis ~~board of directors elects our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director is elected~~ for the term of one year, and until his or her successor is elected and qualified, or until his earlier resignation or removal. The name, address, age and position of our officers and directors are as follows:Opinion

Name and Address of Executive Officer and/or Director		Age		Position
Chen Zu De 9314 FOREST HILL BLVD, #929, WELLINGTON, FL, 33411		62		President, Secretary, Treasurer and Director

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

~~The~~We ~~person~~conducted ~~named~~our ~~above~~audits ~~has~~in ~~held~~accordance ~~his~~with ~~offices/positions~~the ~~since~~standards of the ~~inception~~PCAOB. ofThose ~~our~~standards ~~Company~~require that we plan and isperform ~~expected~~the audits to ~~hold~~obtain ~~said~~reasonable ~~offices/positions~~assurance ~~until~~about whether the ~~next~~financial statements ~~annual~~are ~~meeting~~free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our ~~stockholders~~audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

OnOur ~~December~~audits 28included performing procedures to assess the risks of material misstatement of the financial statements, ~~2022~~whether due to error or fraud, ~~the~~and ~~previous~~performing ~~majority~~procedures ~~shareholder~~that respond ofto ~~Medicale~~those ~~Corp~~risks. ~~(the~~Such ~~“Company”)~~procedures ~~BorisiAlborovi~~included ~~entered~~examining, ~~into~~on a ~~stock~~test ~~purchase~~basis, ~~agreement~~evidence ~~for~~regarding the ~~sale~~amounts ofand 3disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,~~200,000~~ ~~shares~~as well as evaluating ofthe ~~Common~~overall ~~Stock~~presentation of the ~~Company~~financial ~~(the~~statements. ~~“Shares”)~~We tobelieve ~~Magenta~~that ~~Acres,~~our ~~Inc~~audits provide a reasonable basis for our opinion.

AsCritical aAudit result of the acquisition of the Shares, Magenta Acres Inc. holds approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of our Company.Matters

OnCritical ~~December~~audit ~~28,~~matters ~~2022,~~are ~~the~~matters ~~previous~~arising ~~sole officer~~from ~~and~~the ~~director~~current period audit of the ~~Company,~~financial ~~BorisiAlborovi,~~statements ~~resigned~~that ~~his~~were ~~positions~~communicated ~~with~~or ~~the~~required ~~Company.~~to ~~Upon~~be ~~such~~communicated ~~resignations,~~to ~~Chen~~the Board Zuof DeDirectors and that: ~~was~~(1) ~~appointed as~~relate ~~Chief~~to ~~Executive~~accounts ~~Officer,~~or ~~Chairman~~disclosures ofthat are material to the ~~Board,~~financial ~~Treasurer~~statements and ~~Secretary~~(2) involved our especially challenging, subjective, ~~and~~or ~~Director~~complex ofjudgments. ~~the~~We determined that ~~Company~~there are no critical audit matters.

~~Resume~~VICTOR MOKUOLU, CPA PLLC

MrWe ~~Chen~~have ~~Zu De, who was born in 1962 (aged 62),~~ served as ~~Vice-President~~the ofCompany’s ~~Finance~~auditor ofsince ~~Zhejiang Rongye Building Materials Co~~2024., Ltd from May 2017 to October 2022. He served as project team manager and project team lead at Anhui Jiayiyang Technology Co. from February 2009 to March 2017. Prior to this appointment, Mr Chen served in various capacities in technology and construction companies in Zhejiang and Anhui. He attended Zhejiang Lishui University, graduating in 1988 with a degree in Mathematics and Statistics.

~~Committees~~Houston, ~~of the Board~~Texas

~~Our~~January ~~Company currently does not have nominating~~9, ~~compensation~~ or2026 audit committees or committees performing similar functions, nor does our Company have a written nominating, compensation or audit committee charter. Our director believes that it is not necessary to have such committees, at this time, because the functions of such committees can be adequately performed by the sole director.

~~Our~~PCAOB ~~Company~~ID: does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for Directors. The sole director believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum criteria for the election of nominees to the sole director and we do not have any specific process or procedure for evaluating such nominees. The sole director, will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.6771

A shareholder who wishes to communicate with our sole director may do so by directing a written request addressed to our president and director, at the address appearing on the first page of this Prospectus.F-1

7MEDICALE CORP.

~~Corporate~~BALANCE ~~Governance~~SHEETS

The Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with the Securities and Exchange Commission (the “SEC”) and in other public communications made by the Company; and strives to be compliant with applicable governmental laws, rules and regulations. The Company has not formally adopted a written code of business conduct and ethics that governs the Company’s employees, officers and directors as the Company is not required to do so.

	September 30,			September 30,
	2025			2024
ASSETS
Current Assets
Cash	$	–		$	159
Total Current Assets	$	–		$	159


Total Assets	$	–		$	159

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued liabilities	$	10,644		$	–
Accrued interest payable		11,008			3,507
Current liabilities from discontinued operations		12,000			12,000
Total Current Liabilities		33,652			15,507

Non-current convertible note payable		106,434			83,585
Total Long-term Liabilities		106,434			83,585

Total Liabilities		140,086			99,092

STOCKHOLDERS' DEFICIT
Common Stock: $0.0001 par value, 75,000,000 shares authorized, 5,920,000 shares issued and outstanding		592			592
Additional paid-in capital		76,320			76,320
Accumulated deficit		(216,998	)		(175,845	)
Total Stockholders' Deficit		(140,086	)		(98,933	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	–		$	159

InThe ~~lieu~~accompanying ofnotes are an ~~Audit~~integral ~~Committee,~~part ~~the Company’s sole director is responsible for reviewing and making recommendations concerning the selection~~ of ~~outside auditors, reviewing the scope,~~ ~~results~~these ~~and~~audited ~~effectiveness of the annual audit of the Company's~~ financial statements ~~and other services provided by the Company’s independent public accountants~~. ~~The sole director reviews the Company's internal accounting controls, practices and policies.~~

~~Delinquent Section 16(a) Reports~~F-2

~~Our~~MEDICALE ~~common stock is not registered pursuant to Section 12 of the Exchange Act of 1934, as amended (the “Exchange Act”)~~CORP. ~~Accordingly, our officers, directors and principal stockholders are not subject to the beneficial ownership reporting requirements of Section 16(a) of the Exchange Act.~~

~~Code~~STATEMENTS ofOF ~~Business Conduct~~OPERATIONS

We have not adopted a Code of Business Conduct within the meaning of Item 406(b) of Regulation S-K.


	For the Year Ended
	September 30,			September 30,
	2025			2024

Operating Expenses
General and administration	$	33,493		$	54,707
Total operating expenses		33,493			54,707

Net loss from operations		(33,493	)		(54,707	)

Other expense
Other expense		(159	)		–
Interest expense		(7,501	)		(3,506	)
Total other expense		(7,660	)		(3,506	)

Net loss before taxes		(41,153	)		(58,213	)
Provision for income taxes		–			–
Net loss	$	(41,153	)	$	(58,213	)

Net Loss Per Common Share – Basic and Diluted	$	(0.01	)	$	(0.01	)

Weighted Average Common Shares Outstanding		5,920,000			5,920,000

~~Board~~The ~~Committees~~accompanying notes are an integral part of these audited financial statements.

~~We do not have any Board Committees.~~F-3

~~Item~~MEDICALE 11CORP. ~~Executive Compensation.~~

~~The~~STATEMENTS ~~table~~OF ~~below~~STOCKHOLDERS’ ~~summarizes the total compensation earned by each of our named executive Officers (“NEOs”) for each of the fiscal years listed.~~DEFICIT

~~SUMMARY~~For ~~COMPENSATION~~the ~~TABLE~~Years Ended September 30, 2025 and 2024

Management Compensation


	Common stock				Paid-in		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Deficit

Balance, September 30, 2023		5,920,000	$	592	$	76,320	$	(117,632	)	$	(40,720	)
Net loss		–		–		–		(58,213	)		(58,213	)
Balance, September 30, 2024		5,920,000	$	592	$	76,320	$	(175,845	)	$	(98,933	)
Net loss		–		–		–		(41,153	)		(41,153	)
Balance, September 30, 2025		5,920,000	$	592	$	76,320	$	(216,998	)	$	(140,086	)

The ~~following~~accompanying ~~tables~~notes ~~set~~are ~~forth~~an ~~certain~~integral ~~information~~part of ~~about~~these ~~compensation~~audited ~~paid,~~financial ~~earned or accrued for services by our sole officer and director from September 30, 2021 until September 30, 2024:~~statements.

Name and Principal Position	Years	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation ($)	All Other Compensation ($)	Total ($)
BorisiAlborovi, President,	2022	12,000	-0-	-0-	-0-	-0-	-0-	-0-	12,000
Treasurer and Secretary(Former)
Chen Zu De, President,	2023	-0-	-0-	-0-	-0-	-0-	-0-	-0-	-0-
Treasurer and Secretary(Current)	2024	-0-	-0-	-0-	-0-	-0-	-0-	-0-	-0-

F-4

~~Mr.~~MEDICALE ~~Albrovi is reimbursed for any out-of-pocket expenses that he incurs on our behalf~~CORP. In the future, we may approve payment of salaries for officers and directors, but currently, no such plans have been approved. We also do not currently have any benefits, such as health or life insurance, available to our employees.

8STATEMENTS OF CASH FLOWS

Compensation of Directors


	For the Year Ended
	September 30,			September 30,
	2025			2024

Cash Flows from Operating Activities:
Net loss	$	(41,153	)	$	(58,213	)
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in operating assets and liabilities:
Accounts payable		10,644			(4,892	)
Accrued interest payable		7,501			–
Related party short term advance		–			(20,480	)
Net Cash Used in Operating Activities		(23,008	)		(83,585	)

Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes		22,849			83,585
Net Cash Provided by Financing Activities		22,849			83,585

Net Change in Cash and Cash Equivalents		(159	)		–
Cash and Cash Equivalents, beginning of period		159			159
Cash and Cash Equivalents, end of period	$	–		$	159

Supplemental Disclosure Information:
Cash paid for interest	$	–		$	–
Cash paid for taxes	$	–		$	–

~~Directors~~See ~~are~~accompanying ~~permitted~~notes, towhich ~~receive~~are ~~fixed~~an ~~fees and~~integral ~~other compensation for their services as directors. The Board~~ part of ~~Directors~~these ~~has~~audited ~~the~~financial ~~authority to fix the compensation of directors~~statements. ~~No amounts have been paid to, or accrued to, our director in such capacity.~~

~~Stock Plan~~F-5

WeMEDICALE ~~have not adopted a stock plan but may do so in the future~~CORP.

~~Employment~~NOTES ~~Agreements~~TO THE AUDITED FINANCIAL STATEMENTS

~~The~~FOR ~~executive~~THE ~~officer~~YEARS isENDED ~~currently~~SEPTEMBER ~~not~~30, a2025 ~~party to~~AND ~~any employment agreement with us.~~2024

~~Director~~Note ~~Independence~~1 – ORGANIZATION AND NATURE OF BUSINESS

~~Our~~MEDICALE ~~securities~~CORP ~~are~~(“the ~~not currently traded on any public exchange and as such~~Company,”, “we,” “us” ~~are~~or ~~not~~“our”) ~~currently~~was ~~subject~~incorporated toin ~~corporate~~the ~~governance~~State ~~standards~~ of ~~listed~~Nevada ~~companies,~~on ~~which~~August ~~require~~17, ~~among other~~2020. ~~things,~~We ~~that~~plan ~~the~~to ~~majority~~offer ofconsulting ~~the~~services and ~~board~~distribution of ~~directors~~the bedietary ~~independent~~supplements. A Wedietary ~~are~~supplement ~~not~~is ~~currently~~a ~~subject~~manufactured product intended to ~~corporate~~supplement ~~governance~~the ~~standards~~diet when ~~defining~~taken ~~the~~by ~~independence~~mouth ofas ~~our~~a ~~directors~~pill, ~~and~~capsule, wetablet, ~~have~~or ~~chosen~~liquid. toA ~~define~~supplement ancan ~~“independent”~~provide nutrients either ~~director~~extracted from food sources or synthetic, individually or in ~~accordance~~combination, ~~with~~in ~~the NASDAQ~~order ~~Global~~to ~~Market’s~~increase ~~requirements~~the ~~for~~quantity ~~independent~~of ~~directors~~their consumption.

~~Under~~On ~~the~~December ~~NASDAQ~~28, ~~rules~~2022, ~~our~~the ~~current~~previous ~~director~~majority ~~does~~shareholder ~~not~~of ~~qualify~~Medicale asCorp. an(the ~~independent~~“Company”) ~~director~~Borisi Alborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.

~~Item~~As 12a result of the acquisition of the Shares, Magenta Acres Inc. ~~Security~~holds ~~Ownership~~approximately 54% of ~~Certain~~the ~~Beneficial~~issued ~~Owners~~and outstanding shares of Common Stock of the Company, and ~~Management~~as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ~~Related~~ultimately, the ~~Stockholder~~direction ~~Matter~~of our Company.

~~SECURITY~~On ~~OWNERSHIP~~December OF28, ~~CERTAIN~~2022, ~~BENEFICIAL~~the ~~OWNERS~~previous ~~AND~~sole ~~MANAGEMENT~~officer and director of the Company, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

~~Directors~~As of the date of this report, the Company had not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and ~~Executive~~continuing ~~Officers~~the Company’s public reporting.

~~The~~Our ~~following~~principal ~~table~~place ~~sets~~of ~~forth~~business ~~the beneficial~~is ~~ownership~~located 9314 ~~(and~~Forest ~~the~~Hill ~~percentages~~Blvd of#929 ~~outstanding shares represented by such beneficial ownership) as of September 30~~Wellington, ~~2024,~~FL of33411 ~~(i)~~which ~~each~~is ~~director, (ii)~~provided ~~the~~to ~~current~~us ~~NEOs~~on ~~named in the “Summary Compensation Table” contained in this Form 10-K and (iii) all current directors and executive officers as~~ a ~~group.~~rent ~~Except~~free asbasis ~~otherwise indicated, we believe that the beneficial owners of the common stock listed below, based on information provided~~ by ~~such~~our ~~owners, have~~ sole ~~investment~~officer and ~~voting power with respect to such shares, subject to community~~ ~~property laws where applicable~~director. ~~Persons,~~Our ~~who~~telephone ~~have~~number ~~the~~is ~~power~~(407) ~~to vote or dispose of common stock of the Company, either alone or jointly with others, are deemed to be beneficial owners of such common stock~~245-7339.

~~Chen~~Note Zu2 ~~De,~~– GOING ~~President, CEO, Treasurer, Secretary and Chairman of the Board. 3,200,000 shares~~CONCERN

~~Certain~~The ~~Stockholders~~accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $216,998 and a working capital deficit of $33,652 as of September 30, 2025. The Company currently has losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

~~The~~Note ~~following~~3 ~~table~~– SUMMARY ~~sets~~OF ~~forth~~SIGNIFICANT ~~certain~~ACCOUNTING information with respect to each person known by us to be the beneficial owner of five percent or more of either class of the Company’s outstanding common stock. The content of this table is based upon the most current information contained in Schedules 13D or 13G filings with the SEC, unless more recent information was obtained.POLICIES

~~Chen~~Basis ~~Zu De, President, CEO, Treasurer, Secretary and Chairman~~ of ~~the Board. 54%~~presentation

~~This~~The ~~percentage~~accompanying isfinancial ~~calculated~~statements ~~based~~have onbeen prepared in accordance with generally accepted accounting principles in the ~~outstanding shares~~United States of ~~5,920,000~~America. asThe ofCompany’s year-end is September 30~~, 2024~~.

9F-6

~~Item~~Use ~~13.~~of ~~Certain Relationships and Related Transactions, and Director Independence.~~Estimates

~~CERTAIN~~The ~~RELATIONSHIPS~~preparation ~~AND~~of ~~RELATED~~financial ~~PARTY~~statements ~~TRANSACTIONS~~in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

~~The~~Cash following table sets forth certain information concerning the number of shares of our common stock owned beneficially as of September 30, 2024by: (i) each person (including any group) known to us to own more than five percent (5%) of any class of our voting securities, (ii) our director, and or (iii) our officer. Unless otherwise indicated, the stockholder listed possesses sole voting and investment power with respect to the shares shown.equivalents

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percentage Of Common Stock
Common	Chen Zu De	3,200,000	54%
Common	All Officers and Directors as a Group (1 person)	3,200,000	54%

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. During the year ended September 30, 2025, the bank account, which was registered under the former Director of the Company, was written off upon the change of director as the Company was not able to recover the fund and bad debt expense of $159 was incurred in the Statements of Operations. As of September 30, 2025 and September 30, 2024, the Company had cash of $0 and $159, respectively.

~~Future~~Fair ~~Sales~~Value byof ~~Existing~~Financial ~~Shareholders~~Instruments

AFASB ~~total~~ASC ofTopic 3820,~~200,000~~ ~~common~~“Fair ~~shares~~Value ~~at $0.0001~~Measurement,” ~~per~~defines ~~share~~fair ~~have~~value ~~been~~as ~~issued~~the toexchange ~~our~~price ~~sole~~that ~~stockholder.~~would ~~They~~be ~~are~~received ~~restricted~~for ~~securities,~~an asasset ~~that~~or ~~term~~paid isto ~~defined~~transfer ina ~~Rule~~liability ~~144~~in of the ~~Rules~~principal ~~and~~or most ~~Regulations~~advantageous ofmarket for the ~~SEC~~asset ~~promulgated~~or ~~under~~liability in an orderly transaction between market participants on the ~~Act~~measurement date. ~~Under~~The ~~Rule~~standards apply ~~144,~~to ~~such~~recurring ~~shares~~and ~~can~~nonrecurring befair ~~publicly~~value ~~sold,~~measurements ~~subject~~of tofinancial ~~volume~~and ~~restrictions~~non-financial assets and liabilities. The Company determines ~~certain~~the ~~restrictions~~fair values of its assets and liabilities based on ~~the~~a ~~manner~~fair value hierarchy that includes three levels of ~~sale,~~inputs ~~commencing~~that ~~six~~may ~~months~~be ~~after~~used ~~their~~to measure ~~acquisition~~fair value.

~~Any~~The ~~sale~~three oflevels ~~shares~~are ~~held~~defined byas the existing stockholder (after applicable restrictions expire) and/or the sale of shares purchased in this offering (which would be immediately resalable after the offering), may have a depressive effect on the price of our common stock in any market that may develop, of which there can be no assurance.follows:

Item 14. Principal Accountant Fees and Services.

Level 1:	defined as observable inputs such as quoted prices in active markets;
Level 2:	defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3:	defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

~~FEES~~Due TOto ~~THE~~its ~~COMPANY’S~~short-term ~~AUDITORS~~nature, the carrying value of cash, accounts payable and accrued liabilities approximated fair value at September 30, 2025.

~~Set~~Income forth below is a summary of certain fees paid to our independent auditGreenGrowth CPAs(formallyGries & Associates, LLC) and Victor Mokuolu. CPA. PLLC, Independent registered public accountants for services for the fiscal years 2024and 2023.Taxes

Fee Category	Fiscal Year 2024		Fiscal Year 2023
Audit Fees	$	24,958	$	6,000
Tax Fees		–		–
All Other Fees		–		–
Total	$	24,958	$	6,000

The Company is a C Corporation under the Internal Revenue Code and a similar section of the state code.

10All income tax amounts reflect the use of the liability method under accounting for income taxes. Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes arising primarily from differences between financial and tax reporting purposes. Current year expense represents the amount of income taxes paid, payable or refundable for the period.

~~Audit~~Deferred ~~Fees~~income taxes, net of appropriate valuation allowances, are determined using the tax rates expected to be in effect when the taxes are actually paid. Valuation allowances are recorded against deferred tax assets when it is more likely than not that such assets will not be realized. When an uncertain tax position meets the more likely than not recognition threshold, the position is measured to determine the amount of benefit or expense to recognize in the financial statements.

~~Audit~~The ~~fees~~Company’s ~~were~~income ~~for~~tax ~~professional~~returns ~~services~~are ~~rendered~~subject into ~~connection~~review ~~with~~and ~~the~~examination ~~audit~~by federal, state and local governmental authorities. As of September 30, 2025, our ~~annual~~year ~~financial~~ended ~~statements~~2020 ~~set~~through 2025 ~~forth~~tax inreturn ~~our~~was ~~Annual~~open ~~Reports~~to onexamination ~~Form~~with ~~10-K~~federal, state and local governmental authorities. To the ~~review~~extent ofpenalties ~~our~~and ~~quarterly~~interest ~~financial~~are ~~statements~~incurred ~~set~~through ~~forth~~an inexamination, ~~our~~they ~~Quarterly~~would ~~Reports~~be onincluded ~~Form~~as ~~10-Q~~part ~~and~~of ~~consents~~operations ~~for~~in ~~other~~the ~~SEC~~statement ~~filings~~of operations.

~~Audit~~F-~~Related Fees~~7

~~Audit-related~~Basic ~~fees~~Income ~~consist~~(Loss) ofPer ~~fees billed for professional services for consultation on accounting matters.~~Share

~~Approval~~The ofCompany ~~Services~~computes ~~Provided~~income (loss) per share in accordance with FASB ASC 260 “Earnings per Share”. Basic loss per share is computed by ~~Independent~~dividing net income (loss) available ~~Registered~~to ~~Public~~common ~~Accounting~~shareholders ~~Firm~~by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. For the years ended September 30, 2025 and 2024, convertible notes were potentially dilutive instruments and were not included in the calculation of diluted loss per shares as their effect would be antidilutive.

The Board of Directors has considered whether the services provided under other non-audit services are compatible with maintaining the auditor’s independence and has determined that such services are compatible. The Board of Directors has adopted policies and procedures for pre-approving all non-audit work performed by the external auditors. The Board of Directors will annually pre-approve services in specified accounting areas. The Board of Directors also annually approves the budget for the annual generally accepted accounting principles (GAAP) audit.

Schedule of antidilutive shares	September 30,		September 30,
	2025		2024
	(Shares)		(Shares)
Convertible notes payable		5,571,569		5,419,243

11Recent Accounting Pronouncements

~~PART~~We IVhave evaluated all recently issued, but not yet effective, accounting pronouncements and do not believe that these accounting pronouncements will have any material impact on our financial statements or disclosures upon adoption.

~~Item~~Recent ~~15.~~Adopted ~~Exhibit~~Accounting ~~and Financial Statement Schedules.~~Standards

In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt-Debt with Conversion and Other Options” and ASC subtopic 815-40 “Hedging-Contracts in Entity’s Own Equity.” The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 removes from U.S. GAAP the separation models for (1) ~~Financial~~convertible ~~Statements~~debt with a CCF and (2) convertible instruments with a beneficial conversion feature (“BCF”). With the adoption of ASU 2020-06, entities will not separately present in equity an embedded conversion feature these debts. The amendments in this update are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The adoption of ASU 2023-09 has not had a material effect on the Company’s statements and disclosures.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The ~~following~~amendments ~~documents~~in ~~are~~this ~~filed~~update asexpand segment disclosure requirements, ~~part~~including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The adoption of ~~this~~ASU ~~report:~~2023-07 has not had a material effect on the Company’s statements and disclosures.

~~The~~In ~~Financial~~December ~~Statements~~2023, ofthe ~~Medicale Corp.~~FASB atissued ~~September~~ASU 30No. 2023-09, Income ~~2024and~~Taxes (Topic 740) - Improvements to Income Tax Disclosures (“ASU 2023-09”), which is intended to enhance the transparency and ~~for~~decision ~~each~~usefulness of ~~the~~income ~~two~~tax ~~fiscal~~disclosures. ~~years~~The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the ~~period~~rate ~~ended~~reconciliation ~~September~~and ~~30,~~income ~~2024,~~taxes ~~together~~paid ~~with~~information. ASU 2023-09 is effective for the ~~reports~~Company prospectively to ofall ~~the~~annual ~~Independent~~periods ~~Registered~~beginning ~~Public Accounting~~after ~~Firms~~December 15, ~~are~~2024. ~~set~~Early ~~forth~~adoption onis ~~pages~~permitted. ~~F-1~~The ~~through F-11~~adoption of ~~this~~ASU ~~Report~~2023-09 has not had a material effect on the Company’s statements and disclosures.

~~(2) Not applicable.~~F-8

~~(3)~~Note ~~Exhibits~~4– COMMON STOCK

	31.1		Certification of the Chief Executive/Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
	32.1		Certification of the Chief Executive/Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002.
	101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
	101.SCH		Inline XBRL Taxonomy Extension Schema Document
	101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
	101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
	101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
	101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
	104		Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101).

The Company has 75,000,000, $0.0001 par value shares of voting common stock authorized.

~~Item~~All 16shares of common stock have voting rights and are identical. ~~Form~~All ~~10-K~~holders ~~Summary~~of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

~~None~~As of September 30, 2025 and September 30, 2024, the Company had 5,920,000 shares issued and outstanding.

12Voting Common Stock

~~SIGNATURES~~All shares of common stock have voting rights and are identical. All holders of shares of voting common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

~~Pursuant~~Non-voting toCommon the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on January 14, 2025.Stock

~~MEDICALE~~All ~~CORP.~~of ~~By:~~the ~~/s/~~other ~~Chen~~terms Zuof Dethe ~~Chen~~Non-Voting ZuCommon Stock Deshall ~~President~~be ~~and~~identical ~~Chief~~to ~~Executive~~the ~~Officer~~Voting Common Stock, except for the right of first refusal that attaches to the Non-Voting Common Stock, as explained in the Company’s Bylaws.

~~Pursuant~~Note to5– CONVERTIBLE ~~the~~NOTE ~~requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on January 14, 2025.~~PAYABLE

Signature Title /s/ Chen Zu De President, Chief Executive Officer, Treasurer, Secretary, Chen Zu De and Director (Principal Executive Officer and Principal Accounting Officer)

Schedule of convertible notes payable	September 30,		September 30,
	2025		2024
December 2023	$	48,186	$	48,186
March 2024		10,602		10,602
June 2024		9,288		9,288
September 2024		15,509		15,509
December 2024		10,000		–
March 2025		4,371		–
June 2025		2,021		–
September 2025		6,457		–
	$	106,434	$	83,585

13On December 31, 2023, the Company entered into a Convertible Note agreement with a third party at $48,186 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on December 31, 2029. The note can be converted to the Company’s common stock at $0.01 per share. As of September 30, 2025, the accrued interest is $6,749.

~~INDEX~~On TOMarch ~~FINANCIAL~~31, ~~STATEMENTS~~2024, the Company entered into a Convertible Note agreement with a third party at $10,602 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.04 per share. As of September 30, 2025, the accrued interest is $1,273.

~~MEDICALE~~On ~~CORP~~June 30, 2024, the Company entered into a Convertible Note agreement with a third party at $9,288 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.04 per share. As of September 30, 2025, the accrued interest is $930.

~~TABLE OF CONTENTS~~F-9

Report of Independent Registered Accounting Firm (ID 6771)	F-2
Balance Sheets as of September 30, 2024 and 2023	F-5
Statements of Operations for the Year ended September 30, 2024 and for the Year ended September 30, 2023	F-6
Statements of Stockholders’ Deficit for the Year ended September 30, 2024 and for the Year ended September 30, 2023	F-7
Statements of Cash Flows for the Year ended September 30, 2024 and for the Year ended September 30, 2023	F-8
Notes to the Financial Statements	F-9

On September 30, 2024, the Company entered into a Convertible Note agreement with a third party at $15,509 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.15 per share. As of September 30, 2025, the accrued interest is $1,241.

~~F-1~~On December 31, 2024, the Company entered into a Convertible Note agreement with a third party at $10,000 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.15 per share. As of September 30, 2025, the accrued interest is $598.

~~REPORT~~On OFMarch ~~INDEPENDENT~~31, ~~REGISTERED~~2025, ~~PUBLIC~~the ~~ACCOUNTING~~Company entered into ~~FIRM~~a Convertible Note agreement with a third party at $4,371 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on March 31, 2031. The note can be converted to the Company’s common stock at $0.15 per share. As of September 30, 2025, the accrued interest is $175.

~~VICTOR~~On ~~MOKUOLU~~June 30, ~~CPA~~2025, ~~PLLC~~the ~~Accounting~~Company |entered ~~Advisory~~into |a ~~Assurance~~Convertible Note &agreement ~~Audit~~with |a ~~Tax~~third party at $2,021 for paying operating expenses on behalf of the Company. The note bears a 8% interest rate per year and matures on June 30, 2031. The note can be converted to the Company’s common stock at $0.15 per share. As of September 30, 2025, the accrued interest is $41.

ToOn September 30, 2025, the ~~Board~~Company entered into a Convertible Note agreement with a third party at $6,457 for paying operating expenses on behalf of ~~Directors~~the Company. The note bears a 8% interest rate per year and ~~Stockholders~~matures on September 30, 2031. The note can be converted to the Company’s common stock at $0.15 per share. As of September 30, 2025, the accrued interest is $0.

~~Medicale~~During ~~Corp~~the nine months ended September 30, 2025 and 2024, the Company incurred $7,501 and $3,506 note interest expense. As of September 30, 2025 and September 30, 2024, accrued interest payable was $11,008 and $3,507, respectively.

~~Opinion~~Note on6– INCOME ~~the Financial Statements~~TAXES

WeThe ~~have~~Company ~~audited~~provides for ~~the~~income ~~accompanying~~taxes ~~balance~~under ~~sheet of~~ASC ~~Medicale~~740, ~~Corp~~“Income Taxes.” Under (the ~~Company)~~asset ~~as of September 30, 2024,~~ and ~~the~~liability ~~related~~method ~~statements~~ of ~~operations,~~ASC ~~stockholders’ deficit~~740, ~~and~~deferred ~~cash~~tax ~~flows~~assets ~~for the year ended September 30, 2024,~~ and ~~the~~liabilities ~~related~~are ~~notes~~recorded ~~(collectively~~based ~~referred~~on ~~to as~~ the ~~financial~~differences ~~statements).~~between ~~In our opinion,~~ the financial ~~statements~~statement ~~present~~and ~~fairly,~~tax inbasis ~~all~~of ~~material~~assets ~~respects,~~and liabilities and the ~~financial~~tax ~~position~~rates ofin ~~the~~effect ~~Company~~when asthese ofdifferences ~~September~~are ~~30,~~expected ~~2024,~~to ~~and the~~reverse. ~~results~~A ofvaluation ~~its~~allowance ~~operations~~is ~~and~~provided ~~its~~for ~~cash~~certain ~~flows~~deferred ~~for~~tax ~~the~~assets if ~~year~~it ~~ended~~is ~~September~~more ~~30,~~likely ~~2024,~~than innot ~~conformity~~that ~~with~~the ~~accounting~~Company ~~principles~~will ~~generally accepted~~not inrealize ~~the~~tax ~~United~~assets ~~States~~through offuture ~~America~~operations.

~~Substantial~~The ~~doubt~~components ~~about~~of the Company’s ~~ability~~ deferred tax asset and reconciliation of income taxes computed at the statutory rate to ~~continue~~the income tax amount recorded as aof ~~Going~~September ~~concern~~30, 2025 and 2024, are as follows:

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Reconciliation of deferred tax asset	September 30,			September 30,
	2025			2024
Net operating loss carryforward	$	(217,001	)	$	(175,848	)
Statutory tax rate		21%			21%
Deferred tax asset		(45,570	)		(36,928	)
Less: Valuation allowance		45,570			36,928
Net deferred asset	$	–		$	–

~~Basis~~As of September 30, 2025, the Company had approximately $217,000 in net operating losses (“NOLs”) that may be available to offset future taxable income. NOLs generated in tax years prior to September 30, 2017, can be carryforward for ~~Opinion~~twenty years, whereas NOLs generated after September 30, 2017 can be carryforward indefinitely. In accordance with Section 382 of the U.S. Internal Revenue Code, the usage of the Company’s net operating loss carry forwards is subject to annual limitations following greater than 50% ownership changes. Tax returns for the years ended 2020 through 2025 are subject to review by the tax authorities.

~~These~~Note ~~financial~~7– SUBSEQUENT statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.EVENTS

WeIn ~~conducted our audit in~~ accordance with ~~the standards~~SFAS of165 ~~the~~(ASC ~~PCAOB.~~855-10) ~~Those standards require that we plan and perform~~ the ~~audit to obtain reasonable assurance about whether the financial~~Company ~~statements~~has ~~are~~analyzed ~~free~~its ofoperations ~~material~~subsequent ~~misstatement, whether due~~ to ~~error~~September ~~or fraud. The Company is not required to have~~30, ~~nor~~2025 ~~were we engaged~~ to ~~perform,~~the andate ~~audit~~these ~~of its internal control over~~ financial ~~reporting.~~statements Aswere ~~part~~issued ofand ~~our~~has ~~audit,~~determined ~~we are required to obtain an understanding~~that ofit ~~internal~~does ~~control over financial reporting, but~~ not ~~for~~have ~~the~~any ~~purpose~~material ofsubsequent ~~expressing~~events anto ~~opinion~~disclose onin ~~the~~these ~~effectiveness of the Company’s internal control over~~ financial ~~reporting~~statements. ~~Accordingly, we express no such opinion.~~

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.F-10

~~www~~ITEM 9.~~vmcpafirm.com~~ |CHANGES ~~Ph:~~IN ~~713.588.6622~~AND |DISAGREEMENTS ~~Fax:~~WITH ~~1.833.694.1494~~ACCOUNTANTS |ON ~~[email~~ACCOUNTING ~~protected]~~AND FINANCIAL DISCLOSURE

~~F-2~~None.

~~VICTOR~~ITEM ~~MOKUOLU,~~9A. ~~CPA~~CONTROLS ~~PLLC~~AND ~~Accounting | Advisory | Assurance & Audit | Tax~~PROCEDURES

~~Other~~Evaluation ~~Matters~~Of Disclosure Controls And Procedures

~~The~~Under ~~audit~~the ofsupervision and with the ~~accompanying~~participation of ~~balance~~our ~~sheet~~management, ofincluding our principal executive officer and principal financial officer (our chief executive officer), we have conducted ~~Medicale~~an ~~Corp.~~evaluation asof the effectiveness of ~~September~~the ~~30,~~design ~~2023~~and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the ~~related~~Securities ~~statements~~and Exchange Act of ~~operations~~1934, ~~stockholders’~~as ~~deficit~~of the end of the period covered by this report. Based on this evaluation, our principal executive officer and ~~cash~~principal ~~flows~~financial ~~for~~officer concluded as of the evaluation date that our disclosure controls ~~year~~and ~~ended~~procedures ~~September~~were 30ineffective such that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, ~~2023~~including our principal executive and financial officer, recorded, processed, summarized and reported within the ~~related~~time ~~notes~~periods ~~(collectively~~specified ~~referred~~in toSecurities asand ~~the~~Exchange ~~financial~~Commission ~~statements)~~rules ~~was~~and ~~performed~~forms byrelating ~~another~~to ~~Independent~~our Company, particularly ~~Registered~~during ~~Public~~the ~~Accounting~~period ~~Firm,~~when ~~Greengrowth~~this ~~CPAs~~report was being prepared.

~~Victor~~Management’s ~~Mokuolu,~~Annual ~~CPA~~Report ~~PLLC~~On Internal Control Over Financial Reporting

WeOur ~~have~~management ~~served~~is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange ~~Company’s~~Act, ~~auditor~~for ~~since~~our ~~2024~~Company.

~~Houston~~Internal control over financial reporting includes those policies and procedures that: (1) pertain to the maintenance of records that, ~~Texas~~in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of its management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

~~January~~Management 14recognizes that there are inherent limitations in the effectiveness of any system of internal control, ~~2025~~and accordingly, even effective internal control can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect material misstatements. In addition, effective internal control at a point in time may become ineffective in future periods because of changes in conditions or due to deterioration in the degree of compliance with our established policies and procedures.

~~PCAOB~~A ~~ID:~~material ~~6771~~weakness is a significant deficiency, or combination of significant deficiencies, that results in there being a more than remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

~~www.vmcpafirm.com~~Under |the ~~Ph:~~supervision ~~713.588.6622~~and |with ~~Fax:~~the 1participation of our chief executive officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting, as of September 30, 2025, based on the framework set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).~~833.694.1494~~ |Based ~~[email~~on ~~protected]~~our evaluation under this framework, management concluded that our internal control over financial reporting was not effective as of the evaluation date due to the factors stated below.

~~F-3~~10

~~REPORT~~Management OFassessed ~~INDEPENDENT~~the effectiveness of the Company’s ~~REGISTERED~~internal ~~PUBLIC~~control ~~ACCOUNTING~~over ~~FIRM~~financial reporting as of evaluation date and identified the following material weaknesses:

~~Board~~Insufficient Resources: We have an inadequate number of ~~Directors~~personnel with requisite expertise in the key functional areas of finance and ~~Shareholders~~accounting.

~~Medicale~~Inadequate ~~Corp~~Segregation Of Duties: We have an inadequate number of personnel to properly implement control procedures.

~~Opinion~~Lack Of Audit Committee & Outside Directors On The Company’s Board Of Directors: We do not have a functioning audit committee or outside directors on our board of directors, resulting in ineffective oversight in the ~~Financial~~establishment ~~Statements~~and monitoring of required internal controls and procedures.

WeManagement ~~have~~is ~~audited~~committed ~~the~~to ~~accompanying~~improving ~~balance~~its ~~sheets of~~internal controls ~~Medicale~~and ~~Corp. as~~will of(1) ~~September~~continue ~~30,~~to ~~2023,~~use ~~and~~third ~~the~~party ~~related~~specialists ~~statements~~to ofaddress ~~operations,~~shortfalls ~~stockholders’~~in ~~deficit~~staffing and ~~cash~~to ~~flows~~assist ~~for~~ the ~~year~~Company ~~ended~~with ~~September~~accounting ~~30, 2023,~~ and ~~the~~finance ~~related~~responsibilities, ~~notes~~(2) toincrease the ~~financial~~frequency ~~statements.~~of Inindependent ~~our~~reconciliations ~~opinion,~~of ~~the~~significant ~~financial~~accounts ~~statements~~which ~~present~~will ~~fairly,~~mitigate ~~in all material~~the ~~respects,~~lack ~~the~~of ~~financial~~segregation ~~position~~ of ~~Medicale~~duties ~~Corp.~~until asthere ofare ~~September~~sufficient ~~30,~~personnel ~~2023,~~ and ~~the~~(3) ~~results~~may ofconsider ~~its~~appointing ~~operations~~outside directors and ~~its~~audit ~~cash flows for~~committee ~~the~~members ~~period then ended,~~ in ~~conformity with accounting principles generally accepted in~~ the ~~United States of America~~future.

~~Going~~Management, ~~Concern~~including our chief executive officer, has discussed the material weakness noted above with our independent registered public accounting firm. Due to the nature of this material weakness, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected.

~~The~~This ~~accompanying~~annual ~~financial~~report ~~statements~~does ~~have~~not ~~been~~include ~~prepared~~an ~~assuming that~~attestation ~~the~~report ~~entity~~of ~~will~~our ~~continue~~registered aspublic aaccounting ~~going~~firm ~~concern.~~regarding Asinternal ~~discussed~~control inover ~~Note 2 to the~~ financial ~~statements, the Company has suffered recurring losses from operations and has not yet generated any revenues~~reporting. ~~This raises substantial doubt about the Company~~Management’s ~~ability~~report towas ~~continue as~~not asubject ~~going~~to ~~concern.~~attestation ~~Management's~~by ~~plans~~the inour ~~regard~~registered topublic ~~these~~accounting ~~matters~~firm ~~are~~pursuant ~~also~~to ~~described~~temporary inrules ~~Note~~of ~~2 to~~ the ~~financial~~SEC ~~statements. The financial statements do not include any adjustments~~ that ~~might~~permit ~~result~~us ~~from~~to ~~the~~provide ~~outcome~~only management’s ofreport in this ~~uncertainty~~annual report.

~~Basis~~Changes ~~for~~In ~~Opinion~~Internal Controls Over Financial Reporting

~~These~~There ~~financial~~have ~~statements~~been ~~are~~no ~~the~~changes ~~responsibility~~in ofour ~~the~~internal ~~entity’s~~control ~~management.~~over ~~Our~~financial ~~responsibility~~reporting isthat tooccurred ~~express~~during anthe ~~opinion~~last onfiscal ~~these~~quarter ~~financial~~for ~~statements~~our ~~based~~fiscal onyear ~~our~~ended ~~audits.~~September We30, ~~are~~2025 athat ~~public~~have ~~accounting~~materially ~~firm~~affected, ~~registered~~or ~~with the Public Company Accounting Oversight Board (United States) ("PCAOB") and~~ are ~~required~~reasonably tolikely ~~be independent with respect~~ to ~~Medicale~~materially ~~Corp.~~affect, inour ~~accordance~~internal ~~with~~control ~~the~~over ~~U.S.~~financial ~~federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB~~reporting.

WeITEM ~~conducted our audits in accordance with the standards of the PCAOB~~9B. ~~Those~~ ~~standards~~OTHER require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Medicale Corp. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express no such opinion.INFORMATION

~~Our~~Except ~~audits~~as ~~included~~provided ~~performing~~above, ~~procedures~~there tois ~~assess~~no ~~the risks of material~~information ~~misstatement of the financial statements, whether due~~ to ~~error~~be ordisclosed ~~fraud,~~in ~~and~~a ~~performing~~report ~~procedures that respond to those risks. Such procedures included examining,~~ on aForm ~~test~~8-K ~~basis,~~during ~~evidence regarding~~ the ~~amounts~~fourth ~~and~~quarter ~~disclosures~~of in the ~~financial~~year ~~statements.~~covered ~~Our audits also included evaluating the accounting principles used and significant estimates made~~ by ~~management,~~this asForm ~~well~~10-K asthat ~~evaluating~~has ~~the~~not ~~overall~~been ~~presentation~~previously filed ofwith the ~~financial~~Securities ~~statements.~~and WeExchange ~~believe that our audits provide a reasonable basis for our opinion~~Commission.

~~GreenGrowth~~Rule 10b5-1 ~~CPAs~~Trading Plans. - During the three months ended September 30, 2025, no director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

~~December~~We 29do not maintain insider trading policies and procedures governing the purchase, ~~2023~~sale, and/or other dispositions of our securities by our directors, officers, and employees that we believe are reasonably designed to promote compliance with insider trading laws, rules, and regulations applicable to us. We have failed to do so due to limited number of members of management, limited resources, and the lack of equity awards granted to management.

~~We served as the Company’s auditor in 2023~~11

~~Los~~PART ~~Angeles, California~~III

~~PCAOB~~ITEM ID10. ~~Number~~DIRECTORS, ~~6580~~EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

~~F-4~~All directors of our Company hold office until the next annual meeting of the security holders or until their successors have been elected and qualified. The officers of our Company are appointed by our board of directors and hold office until their death, resignation or removal from office. Our directors and executive officers, their ages, positions held, and duration as such, are as follows:

MEDICALE CORP.

Name		Position Held with the Company		Age		Date First Elected or Appointed
Chen Zu De		President, Secretary, Treasurer and Director		63		December 28, 2022

~~BALANCE~~The ~~SHEETS~~person named above has held his offices/positions since the inception of our Company and is expected to hold said offices/positions until the next annual meeting of our stockholders.

	September 30, 2024			September 30, 2023
ASSETS
Current Assets
Cash	$	159		$	159
Total current assets		159			159
Total Assets	$	159		$	159
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Related party advances	$	–		$	20,480
Accounts payable and accrued expenses		3,507			8,399
Current liabilities from discontinued operations		12,000			12,000
Total Current Liabilities		15,507			40,879
Long term Liabilities
Non-Current Convertible Note Payable		83,585			–
Total Long-term Liabilities		83,585			–
Total Liabilities		99,092			40,879
Stockholders’ Deficit
Common stock, $0.0001 par value, 75,000,000 shares authorized; 5,920,000 shares issued and outstanding		592			592
Additional paid-in-capital		76,320			76,320
Accumulated deficit		(175,845	)		(117,632	)
Total Stockholders’ Deficit		(98,933	)		(40,720	)
Total Liabilities and Stockholders’ Deficit	$	159		$	159

On December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) BorisiAlborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.

~~See~~As ~~accompanying~~a ~~notes~~result of the acquisition of the Shares, ~~which~~Magenta ~~are~~Acres anInc. ~~integral~~holds ~~part~~approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of ~~these~~our ~~financial~~board ~~statements~~of directors, all matters upon which shareholder approval is required and, ultimately, the direction of our Company.

~~F-5~~On December 28, 2022, the previous sole officer and director of the Company, BorisiAlborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

~~MEDICALE~~Business ~~CORP.~~Experience

~~STATEMENTS~~The OFfollowing ~~OPERATIONS~~is a brief account of the education and business experience during at least the past five years of each director, executive officer and key employee of our Company, indicating the person’s principal occupation during that period, and the name and principal business of the organization in which such occupation and employment were carried out.

	For the year ended September 30, 2024			For the year ended September 30, 2023
OPERATING EXPENSES
General and Administrative Expenses	$	54,707		$	37,593
TOTAL OPERATING EXPENSES		54,707			37,593
NET LOSS FROM OPERATIONS		(54,707	)		(37,593	)
OTHER EXPENSES
Interest Expense		3,506			–
TOTAL OTHER EXPENSES		3,506			–
LOSS BEFORE TAXES		(58,213	)		(37,593	)
PROVISION FOR INCOME TAXES		–			–
Loss from continuing operations		(58,213	)		(37,593	)
Income(loss) from discontinued operations		–			455
NET LOSS	$	(58,213	)	$	(37,138	)
NET LOSS PER SHARE; BASIC AND DILUTED	$	(0.01	)	$	(0.01	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING; BASIC AND DILUTED		5,920,000			5,920,000

Chen Zu De – President, Secretary, Treasurer and Director

~~See~~Mr ~~accompanying~~Chen ~~notes~~Zu De, ~~which~~who ~~are~~was anborn ~~integral~~in ~~part~~1962 (aged 62), served as Vice-President of ~~these~~Finance ~~financial~~of ~~statements~~Zhejiang Rongye Building Materials Co., Ltd from May 2017 to October 2022. He served as project team manager and project team lead at Anhui Jiayiyang Technology Co. from February 2009 to March 2017. Prior to this appointment, Mr Chen served in various capacities in technology and construction companies in Zhejiang and Anhui. He attended Zhejiang Lishui University, graduating in 1988 with a degree in Mathematics and Statistics.

~~F-6~~Employment Agreements

~~MEDICALE~~We ~~CORP~~have no formal employment agreements with any of our directors or officers.

~~STATEMENT~~Family ~~OF STOCKHOLDERS’ DEFICIT~~Relationships

~~For the~~There ~~Years~~are ~~Ended~~no ~~September~~family 30relationships between any of our directors, ~~2024~~executive officers and ~~2023~~proposed directors or executive officers.

	Common Stock				Additional Paid-in		Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance, September 30, 2022		5,920,000	$	592	$	25,128	$	(80,494	)	$	(54,774	)
Debt forgiveness by related party		–		–		51,192		–			51,192
Net loss for the period ended September 30, 2023		–		–		–		(37,138	)		(37,138	)
Balance, September 30, 2023		5,920,000	$	592	$	76,320	$	(117,632	)	$	(40,720	)
Net loss for the period ended September 30, 2023		–		–		–		(58,213	)		(58,213	)
Balance, September 30, 2024		5,920,000	$	592	$	76,320	$	(175,845	)	$	(98,933	)

~~See~~Involvement ~~accompanying~~in ~~notes,~~certain ~~which~~legal ~~are an integral part of these financial statements~~proceedings.

~~F-7~~To the best of our knowledge, none of our directors or executive officers has, during the past ten years:

~~MEDICALE~~1. ~~CORP~~been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offences); 2. had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time; 3. been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity; 4. been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated; 5. been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or 6. been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26)), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29)), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

~~STATEMENTS~~Section OF16(a) ~~CASH~~Beneficial ~~FLOWS~~Ownership Reporting Compliance

	For the year ended September 30, 2024			For the year ended September 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$	(58,213	)	$	(37,593	)
Net income (loss) for the period from discontinued operation		–			455
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		(4,892	)		11,399
Related party short term advance		(20,480	)		–
CASH FLOWS USED IN OPERATING ACTIVITIES		(83,585	)		(25,739	)
CASH FLOWS FROM INVESTING ACTIVITIES		–			–
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Convertible Note		83,585			–
Proceeds from related party short term advances		–			25,898
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		83,585			25,898
NET INCREASE IN CASH		–			159
Cash and equivalents at beginning of the period		159			–
Cash and equivalents at end of the period	$	159		$	159
Supplemental cash flow information:
Cash paid for:
Interest	$	–		$	–
Taxes	$	–		$	–
Non-cash investing and financing activities:
Debt forgiveness by related party	$	–		$	51,192

Our common stock is not registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, our executive officers and directors and persons who own more than 10% of a registered class of our equity securities are not subject to the beneficial ownership reporting requirements of Section 16(1) of the Exchange Act.

~~See~~Code ~~accompanying notes, which are an integral part~~ of ~~these financial statements.~~Ethics

~~F-8~~We do not currently have a Code of Ethics in place for the Company. Our business operations are not complex and are very limited. Our Company seeks advice and counsel from outside experts such as our lawyers and accountants on matters relating to corporate governance and financial reporting.

~~MEDICALE~~Board ~~CORP.~~and Committee Meetings

~~NOTES~~Our TOboard ~~THE~~of ~~FINANCIAL~~directors ~~STATEMENTS~~held no formal meetings during the year ended September 30, 2025. All proceedings of the board of directors were conducted by resolutions consented to in writing by all the directors and filed with the minutes of the proceedings of the directors. Such resolutions consented to in writing by the directors entitled to vote on that resolution at a meeting of the directors are, according to the Colorado Revised Statutes and our Bylaws, as valid and effective as if they had been passed at a meeting of the directors duly called and held.

~~FOR THE YEARS ENDED SEPTEMBER 30, 2024 and 2023~~13

~~Note~~Nomination ~~1 – ORGANIZATION AND NATURE OF BUSINESS~~Process

~~MEDICALE~~As ~~CORP~~of ~~(“the~~September ~~Company~~30,” 2025, “we,” did not effect any ~~“us”~~material orchanges “to the procedures by which our”) ~~was~~shareholders ~~incorporated~~may inrecommend ~~the~~nominees ~~State~~to our board of ~~Nevada~~directors. onOur ~~August~~board ~~17,~~of ~~2020.~~directors does Wenot ~~plan~~have toa ~~offer~~policy ~~consulting~~with ~~services and~~regards ~~distribution~~to the consideration of ~~the~~any ~~dietary~~director ~~supplements~~candidates recommended by our shareholders. AOur ~~dietary~~board ~~supplement~~of directors has determined that it is ain ~~manufactured~~the ~~product~~best ~~intended~~ position to ~~supplement~~evaluate our Company’s requirements as well as the ~~diet~~qualifications of each candidate when ~~taken~~the byboard ~~mouth~~considers asa nominee for a ~~pill,~~position ~~capsule,~~on ~~tablet,~~our orboard ~~liquid~~of directors. AIf ~~supplement~~shareholders ~~can~~wish ~~provide nutrients either extracted~~to ~~from~~recommend ~~food~~candidates ~~sources~~directly orto our ~~synthetic~~board, ~~individually~~they ormay indo ~~combination,~~so inby ~~order~~sending communications to ~~increase~~the president of our Company at the ~~quantity~~address on the cover of ~~their~~this ~~consumption~~annual report.

OnAudit December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.Committee

AsCurrently aour ~~result~~audit ofcommittee ~~the~~consists ~~acquisition~~ of ~~the Shares,~~our ~~Magenta~~entire ~~Acres~~board ~~Inc~~of directors. ~~holds~~We ~~approximately~~do ~~54%~~not ofhave ~~the~~a ~~issued~~standing ~~and~~audit ~~outstanding~~committee ~~shares~~as ofwe ~~Common~~currently ~~Stock~~have oflimited ~~the~~working ~~Company,~~capital and asminimal ~~such~~revenues. Should itwe isbe able to ~~unilaterally~~raise ~~control~~sufficient ~~the~~funding ~~election~~to ofexecute our ~~board~~business ~~of directors~~plan, ~~all~~we ~~matters~~will ~~upon~~form ~~which~~an ~~shareholder~~audit, ~~approval~~compensation iscommittee ~~required~~ and, ~~ultimately,~~other applicable ~~the~~committees ~~direction~~utilizing of our ~~Company~~directors’ expertise.

OnAudit ~~December~~Committee ~~28,~~Financial 2022, the previous sole officer and director of the Company, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.Expert

AsCurrently ofour ~~the~~audit ~~date~~committee consists of ~~this report, the Company had~~our ~~not~~entire ~~yet~~board ~~commenced~~of ~~any operations~~directors. ~~All~~We ~~activity~~do ~~through~~not ~~the~~currently ~~date~~have ofa ~~this~~director ~~report~~who ~~relates~~is qualified to ~~preserving~~act ~~cash,~~as ~~attempting~~the tohead ~~raise~~of ~~capital, and continuing~~ the ~~Company’s~~audit ~~public reporting~~committee.

~~Our~~ITEM ~~principal place of business is located 9314 Forest Hill Blvd #929 Wellington, FL 33411 which is provided to us on a rent free basis by our sole officer and director~~11. ~~Our telephone~~EXECUTIVE ~~number is (407) 245-7339.~~COMPENSATION

~~Note~~The 2following ~~– GOING~~summary ~~CONCERN~~compensation table indicates the cash and non-cash compensation earned during the years ended September 30, 2025 and 2024 by each person who served as chief executive officer and chief financial officer during the years ended September 30, 2025 and 2024.

~~The~~SUMMARY ~~accompanying~~COMPENSATION financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $175,845 and a working capital deficit of 15,348 as of September 30, 2024. The Company currently has losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.TABLE

F-9

Name and Principal Position

Year

Salary
($)

Bonus
($)

Stock Awards
($)

Option Awards
($)

Non-Equity Incentive Plan Compensation
($)

Change in Pension Value and Nonqualified Deferred Compensation Earnings
($)

All Other Compensation
($)

Total
($)

Chen Zu De,

2024

–

President, Treasurer,

2025

–

Secretary and Director

~~Note~~Granting 3of ~~– SUMMARY~~Certain OFEquity ~~SIGNIFICANT~~Awards Close in Time to the Release of ~~ACCOUNTING~~Material ~~POLICIES~~Nonpublic Information

~~Basis~~We do not grant equity awards in anticipation of ~~presentation~~the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time the public release of such information based on award grant dates. During the last completed fiscal year, we have not made awards to any named executive officer or director during the period beginning four business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

~~The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America. The Company’s year-end is September 30.~~14

~~Use~~ITEM of12. ~~Estimates~~SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The ~~preparation~~following oftable ~~financial~~sets ~~statements~~forth incertain ~~conformity~~information ~~with~~concerning USthe ~~GAAP~~number ~~requires~~of ~~management~~shares toof ~~make~~our ~~estimates~~common ~~and~~stock ~~assumptions~~owned ~~that~~beneficially ~~affect~~as ~~the~~of ~~reported~~January ~~amounts~~9, of2026 ~~assets~~by: ~~and~~(i) ~~liabilities~~each ~~and~~person ~~disclosure~~(including any group) ofknown ~~contingent~~to ~~assets~~us ~~and~~to ~~liabilities~~own atmore ~~the~~than ~~date~~five ~~the~~percent ~~financial~~(5%) ~~statements~~of ~~and~~any ~~the~~class ~~reported~~of ~~amount~~our voting securities, (ii) members of ~~revenues~~our ~~and~~Board ~~expenses~~of ~~during~~Directors, ~~the~~and or (iii) ~~reporting~~our ~~period~~executive officers. ~~Actual~~Unless ~~results~~otherwise ~~could~~indicated, ~~differ~~the ~~from~~stockholder ~~those~~listed ~~estimates~~possesses sole voting and investment power with respect to the shares shown.

Cash equivalents

Name and Address of

Beneficial Owner

Amount and Nature of

Beneficial Ownership

Percentage

of Class⁽¹⁾

Chen Zu De, President, CEO, Treasurer, Secretary and Director

3,200,000 Share of Common Stock / Direct

54.00%

Directors and Executive Officers as a Group

3,200,000 Shares of Common Stock

54.00%

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. The cash equivalents as of September 30, 2024 and 2023 were $159 and $159, respectively._________________

~~Fair~~(1) ~~Value~~Under Rule 13d-3, a beneficial owner of ~~Financial~~a ~~Instruments~~security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in this table does not necessarily reflect the person’s actual ownership or voting power with respect to the number of shares of common stock actually outstanding on January 9, 2026. As of January 9, 2026, there were 5,920,000 shares of our Company’s common stock issued and outstanding.

~~The~~Except ~~three~~as ~~levels~~disclosed ~~are~~herein, ~~defined~~no asdirector, ~~follows:~~executive officer, shareholder holding at least 5% of shares of our common stock, or any family member thereof, had any material interest, direct or indirect, in any transaction, or proposed transaction since the year ended September 30, 2025, in which the amount involved in the transaction exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at the year-end for the last three completed fiscal years.

Level 1:	defined as observable inputs such as quoted prices in active markets;
Level 2:	defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3:	defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

~~Due~~The toaggregate ~~its~~fees ~~short-term~~billed ~~nature,~~for the ~~carrying~~most ~~value~~recently ofcompleted ~~cash~~fiscal year ended September 30, ~~director~~2025 ~~loans~~and 2024 for professional services rendered by the principal accountant for the audit of our annual financial statements and ~~issuance~~review of ~~common~~the ~~stock~~financial ~~approximated~~statements ~~fair~~included ~~value~~in atour ~~September~~quarterly ~~30,~~reports ~~2024.~~on Form 10-Q and services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for these fiscal periods were as follows:

Income Taxes

Fee Category	Year Ended September 30, 2025		Year Ended September 30, 2024

Audit Fees	$	19,000	$	24,958
Audit-Related Fees		–		–
Tax Fees		–		–
All Other Fees		–		–
Total Fees	$	19,000	$	24,958

~~The~~Audit ~~Company~~committee ispolicies a& ~~C Corporation under the Internal Revenue Code and a similar section of the state code.~~procedures

~~All~~We ~~income~~do ~~tax~~not ~~amounts~~currently ~~reflect~~have ~~the~~a ~~use~~standing ofaudit ~~the liability method under accounting for income taxes~~committee. ~~Income taxes are provided for the tax effects of transactions reported in the financial~~ ~~statements~~The ~~and~~above ~~consist~~services ofwere ~~taxes~~approved ~~currently~~by ~~due~~our ~~plus~~Board ~~deferred taxes arising primarily from differences between financial and tax reporting purposes. Current year expense represents the amount~~ of ~~income taxes paid, payable or refundable for the period~~Directors.

~~F-10~~15

~~Deferred~~PART income taxes, net of appropriate valuation allowances, are determined using the tax rates expected to be in effect when the taxes are actually paid. Valuation allowances are recorded against deferred tax assets when it is more likely than not that such assets will not be realized. When an uncertain tax position meets the more likely than not recognition threshold, the position is measured to determine the amount of benefit or expense to recognize in the financial statements.IV

~~The~~ITEM ~~Company’s income tax returns are subject to review and examination by federal, state and local governmental authorities~~15. ~~As of September 30~~EXHIBITS, ~~2024,~~FINANCIAL ~~our~~STATEMENT September 30, 2023 tax return was open to examination with federal, state and local governmental authorities. To the extent penalties and interest are incurred through an examination, they would be included as part of operations in the statement of operations.SCHEDULES

~~Long-Lived~~(a) ~~Assets~~Financial ~~– Intangible Assets~~Statements

We account for our intangible assets in accordance with ASC Subtopic 350-30, General Intangibles Other Than Goodwill, and ASC Subtopic 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets. ASC Subtopic 350-30 requires assets to be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Further, ASC Subtopic 350-30 requires an intangible asset to be amortized over its useful life and for the useful life to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs of internally developing, maintaining, or restoring intangible assets are recognized as an expense when incurred.

	(1)	Financial statements for our Company are listed in the index under Item 8 of this document.

	(2)	All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

~~Impairment~~(b) ~~of Long-Lived Assets~~Exhibits

We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. During the year ended September 30, 2024 we recognized $0 of impairment expense.

EXHIBIT NUMBER		Exhibit Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer and Chief Financial Officer
(32)		Section 1350 Certifications
32.1**		Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
(100)		Interactive Data File
101.INS**		XBRL Instance Document
101.SCH**		XBRL Taxonomy Extension Schema Document
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

~~Basic Income (Loss) Per Share~~_________

~~The~~*Filed ~~Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share”~~herewith. Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of September 30, 2024 there were no potentially dilutive debt or equity instruments issued or outstanding.

~~Comprehensive~~**Furnished ~~Income~~herewith.

~~Comprehensive~~ITEM ~~income is defined as all changes in stockholders’ equity, exclusive of transactions with owners, such as capital investments~~16. ~~Comprehensive~~FORM income includes net income or loss, changes in certain assets and liabilities that are reported directly in equity such as translation adjustments on investments in foreign subsidiaries and unrealized gains (losses) on available10-~~for-sale~~K ~~securities. As of September 30, 2024 were no differences between our comprehensive loss and net loss.~~SUMMARY

~~F-11~~None.

~~Recent Accounting Pronouncements~~16

~~We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.~~SIGNATURES

~~Risks~~Pursuant ~~and~~to ~~Uncertainties~~the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations.

	MEDICALE CORP.

Dated: January 12, 2026	By:	/s/ Chen Zu De
		Chen Zu De
		President, Chief Executive Officer, Chief Financial Officer and Director

Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.17

Note 4– COMMON STOCK

The Company has 75,000,000, $0.0001 par value shares of voting common stock authorized.

All shares of common stock have voting rights and are identical. All holders of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

On December 28, 2022, Borisi Alborovi, the previous majority shareholder of Medicale Corp. (the “Company”), entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc.

As of September 30, 2024 the company had 5,920,000 shares issued and outstanding.

As of September 30, 2023 the company had 5,920,000 shares issued and outstanding.

Voting Common Stock

All shares of common stock have voting rights and are identical. All holders of shares of voting common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder.

Non-voting Common Stock

All of the other terms of the Non-Voting Common Stock shall be identical to the Voting Common Stock, except for the right of first refusal that attaches to the Non-Voting Common Stock, as explained in the Company’s Bylaws.

F-12

Note 5 – COMMITMENTS AND CONTINGENCIES

In the normal course of business, the Company may become a party to litigation matters involving claims against it. At September 30, 2024, there are no current matters that would have a material effect on the Company’s financial position or results of operations.

Note 6– RELATED PARTY TRANSACTIONS

The sole officer and director, Borisi Alborovi, was the only related party with whom the Company had transactions with during the period from inception on August 17, 2020 through December 31, 2022.

On December 28, 2022, the previous sole officer and director, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

As a result of the acquisition of the Shares on December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi forgive the debt that due to him, with the amount of $51,192.

As of December 31, 2023 and September 30, 2023, the Company owed Mr. Alborovi $nil and $nil respectively, for operating expenses on behalf of the Company. The amounts due to the related party are unsecured and non-interest bearing with no set terms of repayment.

As of September 30, 2024 and September 30, 2023, the Company owed Chen Zu De $nil and $nil respectively, for operating expenses on behalf of the Company. The amounts due to the related party are unsecured and non-interest bearing with no set terms of repayment.

Note 7– CONVERTIBLE NOTE PAYABLE

On December 31, 2023, the company entered into a Convertible Note agreement with a third party at $48,186. The note bears a 8% interest rate per year and matures on December 31, 2029. The note can be converted to the Company’s common stock at $0.01 per share. As of September 30, 2024, the accrued interest is $2,894.

On March 31, 2024, the company entered into a Convertible Note agreement with a third party at $10,602. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.01 per share. As of September 30, 2024, the accrued interest is $425.

On June 30, 2024, the company entered into a Convertible Note agreement with a third party at $9,288. The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.01 per share. As of September 30, 2024, the accrued interest is $187.

On September 30, 2024, the company entered into a Convertible Note agreement with a third party at $15,509 The note bears a 8% interest rate per year and matures on March 31, 2030. The note can be converted to the Company’s common stock at $0.01 per share. As of September 30, 2024, the accrued interest is $nil.

F-13

Note 8– INCOME TAXES

Our Company has not filed any federal income tax returns and we are currently not subject to state income tax filing requirements. As of September 30, 2024, we have net operating loss carryforwards, on a book basis, of $164,051 which may be available to reduce various future years' federal taxable income. Future tax benefits which may result from these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, we have recorded a valuation allowance for the deferred tax asset relating to the net operating loss carry forwards.

The following table presents the current income tax provision for federal and state income taxes for the years ended September 30, 2024 and 2023:

Schedule of income tax provision
	2024		2023
Current tax provisions:
Federal	$	–	$	–
State		–		–
Total provision for income taxes	$	–	$	–

Reconciliations of the U.S. federal statutory rate to the actual tax rate for the years ended September 30, 2024 and 2023:

Schedule of tax rates
	2024		2023
US federal statutory income tax rate		21.0%		21.0%
Increase in valuation reserve		-21.0%		-21.0%
Total provision for income taxes		0.0%		0.0%

The components of our deferred tax assets as of September 30, 2024 and 2023 consisted of the following:

Schedule of deferred tax assets
	2024			2023
Net operating loss carry forwards	$	36,928		$	24,703
Less: valuation allowance		(36,928	)		(24,703	)
Net deferred tax assets	$	–		$	–

During the year ended September 30, 2024, the valuation reserve increased $12,225 compared to an increase of $7,803 during the year ended September 30, 2023. In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not that our Company will not realize some portion or all of the deferred tax assets. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment. As a result, management determined, as of September 30, 2024, that it was more likely than not the deferred tax assets would not be realized.

As noted above, we have not filed any federal tax returns, but we plan on bringing our tax filings current as soon as is practical.

Note 9– SUBSEQUENT EVENTS

In accordance with SFAS 165 (ASC 855-10) the Company has analyzed its operations subsequent to September 30, 2024 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

F-14

Filing Compare · Medicale Corp.